The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Genentech/Roche; Medivation/Astellas; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Genentech/Roche; Medivation/Astellas; Pfizer; Sanofi
 
Robert Dreicer
Honoraria - Astellas Pharma
Consulting or Advisory Role - Asana Biosciences; Astellas Pharma; Exelixis; Ferring; Janssen Oncology; Medivation; Roche
Research Funding - Asana Biosciences (Inst); Genentech (Inst)
 
Allan J. Pantuck
Stock and Other Ownership Interests - Kite, a Gilead company
Consulting or Advisory Role - Pfizer
Speakers' Bureau - Dendreon
 
Naomi B. Haas
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals (I)
Expert Testimony - Lilly (I)
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - TaiRx, Inc.
Research Funding - Aeglea Biotherapeutics (Inst); Asana Biosciences (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst)
 
Allison Janine Tyler
Honoraria - AstraZeneca; Bayer
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Bayer
Travel, Accommodations, Expenses - AstraZeneca; Bayer
 
Niranjan Sathyanarayana Rao
Employment - Asana Biosciences
Stock and Other Ownership Interests - Asana Biosciences
 
Penelope J. Bristow
Consulting or Advisory Role - Asana Biosciences
 
Sanjeeva Reddy
Employment - Asana Biosciences
Stock and Other Ownership Interests - Asana Biosciences
 
Louis J. Denis
Employment - Asana Biosciences
Leadership - Asana Biosciences
Stock and Other Ownership Interests - Asana Biosciences
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim; Pfizer
Travel, Accommodations, Expenses - Asana Biosciences; Boehringer Ingelheim
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics; ArQule; Asana Biosciences; Astex Pharmaceuticals; Bayer Schering Pharma; Bind Therapeutics; Blend Therapeutics; Celator; Dicerna; Endocyte; Genmab; Heron; Janssen; Johnson & Johnson; Johnson & Johnson; Mersana; Merus; Nanobiotix; Pharmacyclics; Pierre Fabre; Proximagen; Symphony Evolution; Upsher-Smith; Valent Technologies
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Pfizer (Inst); TaiRx, Inc. (Inst)